news.cision.com

Crunchfish Gesture Interaction AB ("Crunchfish") signs a commercial license agreement with Guangdong Virtual Reality Technology CO LTD (“Ximmerse”), to provide Ximmerse’s next generation AR-glasses with Crunchfish’s latest hand tracking technologies - XR Skeleton and XR Skeleton Stereo. Ximmerse will integrate Crunchfish’s software in all new models of AR-glasses to enable touchless interaction. It is a 3-years agreement, with a business model that includes an initial fee of $25,000US as well as a running royalty per produced unit that includes Crunchfish’s software.The agreement gives

HC Andersen Capital Events 17/8: Meet the management in NTG, Xplora and BioPorto

HC Andersen Capital is today hosting several digital events where you can meet and ask questions directly to the top management. It is free for all to attend.NTG - Presentation of the Q2 report 2022On 12 August, Nordic Transport Group A/S published an unsurprisingly strong account for the second quarter of 2022. However, the guidance for 2022 is maintained. Thus, NTG realizes an impressive revenue growth in the quarter of 58.7% y/y, of which 25% is organic, which means that the revenue lands at DKK 2,729 million. against the consensus of DKK 2,597 million. Adjusted EBIT is DKK 216.8

Genova Property Group Interim Report January–June 2022

January–June 2022 period · Rental income amounted to SEK 185.7m (141.8), an increase of 31%. · Net operating income amounted to SEK 132.3m (104.2), an increase of 27%. · Income from property management increased 62% to SEK 56.3m (34.8), of which income from property management attributable to shareholders was SEK 31.1m (11.0), corresponding to SEK 0.74 (0.28) per share. · Net income after tax amounted to SEK 342.5m (263.8), corresponding to SEK 7.06 (6.06) per share. · Long-term net asset value attributable to shareholders increased 42% to SEK 3,649.5m (2,563.0),

Nepa strengthens its growth initiatives and appoints Ferry Wolswinkel as Chief Revenue Officer

STOCKHOLM, Sweden – Nepa has in accordance with its growth strategy established a new role and appointed Ferry Wolswinkel as Chief Revenue Officer (CRO) and new member of the Group Management team. He will be responsible for accelerating the company’s growth, including the global sales and marketing organization, developing its revenue streams and optimizing sales growth in select markets and product categories. Ferry has extensive experience from global sales roles in tech and consumer insight companies, most recently as Vice President Sales for the London-based consumer intelligence

Scandion Oncology extends PANTAX trial due to better-than-expected tolerability of SCO-101

Good tolerability allows for continued dose escalation in the dose-finding PANTAX phase 1b-trial with SCO-101 as combination therapy in pancreatic cancer. Consequently, readout from the trial is now expected in the first half of 2023.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, has observed a better-than-expected tolerability of its potential new cancer treatment SCO-101 in the dose-finding PANTAX phase 1b-trial. Thus, dosing is now escalated to higher levels than expected based

ORGANOCLICK AB (PUBL) PUBLISH INTERIM REPORT FOR Q2 2022

Wed, Aug 17, 2022 08:05 CET

The second quarter had a mixed outcome for the Group. Declining sales in the building supplier market negatively affected sales of our consumer products. On the other hand, we doubled the sales of binders in the Nonwoven and technical textile business unit, through increased deliveries to Duni and Ahlstrom-Munksjö. The net meant a reduction in the Group’s sales by -3.3 (10.4) % to SEK 38.5 (39.8) million.Translation from CEO Mårten Hellbergs comments to the Interim Report. Q2, 1 April - 30 June 2022 The Group compared with 2021 » Net revenue amounted to SEK 38.53 (36.06) million

2020 Bulkers Ltd. (2020) - Results for the second quarter and first half of 2022

Oslo, Norway, August 17, 2022 2020 Bulkers Ltd. (“2020 Bulkers” or the “Company”), today announced its unaudited financial and operating results for the three and six months ended June 30, 2022. Key events during the second quarter of 2022 · The Company reported net profit of US$12.0 million and EBITDA of US$17.4 million for the second quarter of 2022. · Achieved average time charter equivalent earnings of approximately US$32,300 per day, gross. · The Company declared total cash distributions of US$0.52 per share for the months of April, May and June 2022. · In

Episurf Medical provides update on process for UK NICE guidelines

Episurf Medical (NASDAQ: EPIS B) today provides an update on the work related to the UK National Institute for Health and Care Excellence’s (NICE) guidelines. NICE guidelines are evidence-based recommendations for health and care in the UK, to help healthcare professionals in their work. The guidelines also support payors and authorities on their decisions to reimburse various procedures and devices. Episurf Medical has participated in several NICE hearings for its Episealer® knee implant family, and the company has been informed about the timetable, which is likely to result in guidelines

Vicore IPF interim data selected as an oral “late-breaker” at the ERS congress

· The AIR trial is a single arm, multicenter phase 2 study in patients with idiopathic pulmonary fibrosis (IPF) · Interim data have shown stabilization of the disease and an increase in lung capacity at 24 and 36 weeks · Oral presentation by Professor Toby Maher on September 4 at 15:00 CET Gothenburg, August 17, 2022 - Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces that the previously published interim data from AIR, a phase 2 trial in IPF), will be

Notice of Annual General Meeting in Pomegranate Investment AB

NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO ANY U.S. PERSONThe shareholders in Pomegranate Investment AB (publ) with Reg. No. 556967-7247 and registered office in Stockholm are hereby convened to the annual general meeting to be held on 14 September 2022 at 3 p.m. at the offices of Advokatfirman Vinge, Smålandsgatan 20, SE-111 46 Stockholm. Preconditions for participation Shareholders who wish to participate in the general meeting must be included in the shareholders’ register maintained by Euroclear Sweden AB as of 6 September 2022. Nominee registered shares To

TikoMed Announces Appointment of Two Independent Directors

Viken – 17th August, 2022 – Today, Swedish biopharmaceutical company TikoMed AB announced the appointment of two new members to its Board of Directors, Tara Heitner and Pete Zorn. “We are excited to welcome Tara and Pete to our Board,” said Adam Bruce, Founder and Chairman of the Board of TikoMed. “Tara and Pete are perfect fits for our next steps with their strong track records of transactional experience. They bring years of organizational and business development expertise and leadership that will serve the company well as we aim to grow our business focused on the ILB® drug platform

Inify’s first ultramodern laboratory on track

STOCKHOLM – August 17 2022 – Inify Laboratories, a company providing fully digitalized pathology laboratory services for cancer diagnostics, listed in June 2022 on the Euronext Growth in Oslo, is on track in building its first ultramodern laboratory at Campus Solna, Sweden, next to world-leading healthcare. “We signed a five-year leasing contract for our office and laboratory facilities at Campus Solna. These will be Inify’s headquarters, housing our first laboratory as well as our Center of Excellence,” says CEO Fredrik Palm at Inify. The company expects to move into the new facility

Implema partners with Litorina to accelerate growth - Lars Wollung new chairman of the board

Implema, Sweden’s leading implementation specialist for SAP and Microsoft Dynamics enters a new phase in its growth journey as it partners with private equity company Litorina and announces Lars Wollung as chairman of the board. The partnership will enable Implema to accelerate growth by expanding its service offering, strengthening its position as a long-term digital transformation partner. Litorina is a Swedish private equity firm with extensive experience partnering with innovative companies in the Nordics. With this move, Litorina takes a majority stake in Implema, while Implema’s

Remedy Entertainment Oyj: Managers' Transactions – Kaisa Salakka

Remedy Entertainment Oyj – Managers' Transactions 17 August 2022 9.00 a.m. (EEST) ____________________________________________ Person subject to the notification requirementName: Kaisa SalakkaPosition: Member of the BoardIssuer: Remedy Entertainment OyjLEI: 7437003VZ3JPF7DBTG92Notification type: INITIAL NOTIFICATIONReference number: 18520/4/6 ____________________________________________ Transaction date: 2022-08-16Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000251897Nature of the transaction: ACQUISITION Transaction details (1):

SmartCraft ASA (SMCRT) - Invitation to presentation of the second quarter 2022 results and deep dive presentation

Wed, Aug 17, 2022 07:58 CET

SmartCraft ASA | Non-regulatory press releases 17 August 2022 - SmartCraft ASA has the pleasure of inviting investors, analysts, media and other stakeholders to its presentation of the second quarter 2022 financial report followed by a deep-dive presentation of the company’s growth strategy, products and technology. The event will be fully virtual, with opportunity for viewers to ask written questions during and after the event. Time: 25 August 2022 at 9:30-11:00 CET Webcast address: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20220825_2 Program (subject to

Idogen to convene major owners for election to Board

Idogen AB (publ) announced today that an Extraordinary General Shareholder Meeting will be convened to propose the election of two new members to the Board of Directors: Joakim Söderström and Niklas Wallett, representing a consortium that owns approximately 17% of the votes. The election of Joakim Söderström as new Chairman of the Board has also been proposed. Current Board members Leif G. Salford and Lennart Svensson have yielded their positions and their removal from office has been proposed in conjunction with the election of the two new Board members. Current Chairman of the Board

Transactions in connection with share buy-back programme

Wed, Aug 17, 2022 07:51 CET

On 3 March 2022, H+H International A/S (hereinafter referred to as “H+H” or “the Company”) initiated a share buy-back programme in compliance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on Market Abuse and Commission Delegated Regulation (EU) 1052/2016 of 8 March 2016 (the “Safe Harbour Regulation”). The share buy-back programme is expected to be realised over a 12-month period, starting from 4 March 2022. Under the share buy-back programme, H+H may repurchase shares up to a maximum amount of DKK 150 million. Please refer

Lundbeck’s sales increased by +7% (+3% in local currencies) to DKK 8,847 million in the first half of 2022

HIGHLIGHTS Strategic brands are significant growth drivers of strong operational performance growing +27% (+19% in local currencies) in the first half of 2022 representing 63% of overall revenue · Brintellix[®]/Trintellix[®]: +24% reported to DKK 2,051 million (+17% in local currencies) · Rexulti[®]/Rxulti[®]: +29% reported to DKK 1,771 million (+17% in local currencies) · Abilify Maintena[®]: +16% reported to DKK 1,393 million (+11% in local currencies) · Vyepti[®]: +120% reported to DKK 390 million (+100% in local currencies) All markets contribute to revenue momentum

Panoro Energy – Invitation to Half Year 2022 Results Presentation

Oslo, 17 August 2022 - The Half Year 2022 Report to be announced on Wednesday 24 August will be available on our website http://www.panoroenergy.com at 07:30 a.m. CEST. The company will hold a live webinar presentation at 09:00 a.m. CEST on Wednesday 24 August 2022, during which management will discuss the results and operations, followed by a Q&A session. The webinar presentation can be accessed through registering at the link below and the online event will be equipped with features to ask live questions. Joining instructions for participating online or through using local dial-in

QUARTERLY REPORT APRIL TO JUNE 2022

CONTINUED HIGH GROWTH REVENUE TRAJECTORY – QUARTERLY SAAS ARR GROWTH OF 55%APRIL TO JUNE 2022 · Net sales amounted to 10.2 MSEK (8.2), + 24% · Recurring revenues amounted to 9.1 MSEK (6.3), + 44% · SaaS ARR amounted to 20.0 MSEK, +55% compared with March 2022 · SaaS API Call Volumes 9.3 million, + 70% compared with March 2022 · Gross margin 67% (67) · EBITDA adjusted amounted to -22.4 MSEK (-17.2) · Earnings per share (*) amounted to -2.4 SEK (-2.3) JANUARY TO JUNE 2022 · Net sales amounted to 20.3 MSEK (18.1), + 13% · Recurring revenues amounted to 17.8

Interim report 1 January – 30 June 2022

Evaluating strategic optionsSECOND QUARTER 2022 · Revenue increased by 6% to SEK 1,691m (1,590) · Operating profit increased by 2% to SEK 147m (144) · Operating margin decreased to 8.7% (9.0) · The result for the period decreased by 63% to SEK 32m (86) · Basic earnings per share amounted to SEK 2.20 (5.94) · Cash flows from operating activities amounted to SEK 39m (120) JANUARY - JUNE 2022 · Revenue increased by 20% to SEK 3,436m (2,856) · Operating profit increased by 14% to SEK 255m (224) · Operating margin decreased to 7.4% (7.8) · The result for the

Sitowise’s Half-year Report January – June 2022: Double-digit growth in net sales continued

Sitowise Group Plc, Half-year Report 1 January – 30 June 2022, 17 August 2022 at 8:30 am Q2: Double-digit growth in net sales continuedApril–June in brief (Q2) · Net sales increased by 11% to EUR 51.7 (46.5) million. · Organic net sales grew by 4% (-5%). · Adjusted EBITA was EUR 4.9 (5.9) million, or 9.5% (12.7%) of net sales. · The order book increased by 21% to EUR 169 (140) million. · Leverage (net debt / adjusted EBITDA) rose as a result of acquisitions and was 2.7x (1.5x). · Sitowise carried out three acquisitions. In June, the Group was joined by two Finnish

Karo Intressenter AB publishes the offer document for the public cash offer to the shareholders of Karo Pharma Aktiebolag